Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: inflammation therapeutics - VBL Therapeutics

Drug Profile

Research programme: inflammation therapeutics - VBL Therapeutics

Alternative Names: VB-202; VB-302; VB-703

Latest Information Update: 04 Sep 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vascular Biogenics
  • Developer VBL Therapeutics
  • Class Antifibrotics; Hepatoprotectants; Phospholipids; Small molecules
  • Mechanism of Action CD14 antigen inhibitors; Cell movement inhibitors; Cytokine inhibitors; Interleukin 12 subunit p40 inhibitors; Phospholipid modulators; Toll like receptor 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Non-alcoholic steatohepatitis; Renal fibrosis
  • No development reported Atherosclerosis; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 30 Aug 2018 VBL Therapeutics has patent protection for VBL 201 and lecinoxoid programmes in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Atherosclerosis in Israel (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top